ADSB-FUB-187

ADSB-FUB-187

Systematic (IUPAC) name
7-chloro-N-[(2S)-1-[2-(cyclopropylsulfonylamino)ethylamino]-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	1185283-97-9
PubChem	CID: 44186812
Chemical data
Formula	C26H31ClFN5O4S
Molecular mass	564.07 g/mol
SMILES CC(C)(C)[C@@H](C(=O)NCCNS(=O)(=O)C1CC1)NC(=O)C2=NN(C3=C2C=CC=C3Cl)CC4=CC=C(C=C4)F
InChI InChI=1S/C26H31ClFN5O4S/c1-26(2,3)23(25(35)29-13-14-30-38(36,37)18-11-12-18)31-24(34)21-19-5-4-6-20(27)22(19)33(32-21)15-16-7-9-17(28)10-8-16/h4-10,18,23,30H,11-15H2,1-3H3,(H,29,35)(H,31,34)/t23-/m1/s1 Key:UANJTRHQSBHCID-HSZRJFAPSA-N

ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor with a binding affinity of K_i = 0.09 nM and an EC₅₀ of 1.09nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of K_i, it is not the most potent compound at producing a CB₁ mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC₅₀ values.

Legality

Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.

See also

• AB-FUBINACA
• ADB-FUBINACA